Showing 1 - 10 of 5,036
pharmaceuticals on competition by parallel imports. First, I analyze the effect of a manufacturer rebate on competition by parallel …
Persistent link: https://www.econbiz.de/10011949028
We investigate the welfare impact of parallel imports using a large panel data set containing monthly information on sales, ex-factory prices, and further product characteristics for all 700 antidiabetic drugs sold in Germany between 2004 and 2010. We estimate a two-stage nested logit model of...
Persistent link: https://www.econbiz.de/10010481411
We investigate the welfare impact of parallel imports using a large panel data set containing monthly information on sales, ex-factory prices, and further product characteristics for all 700 anti-diabetic drugs sold in Germany between 2004 and 2010. We estimate a two-stage nested logit model of...
Persistent link: https://www.econbiz.de/10010338113
We investigate the welfare impact of parallel imports using a large panel data set containing monthly information on sales, ex-factory prices, and further product characteristics for all 700 anti-diabetic drugs sold in Germany between 2004 and 2010. We estimate a two-stage nested logit model of...
Persistent link: https://www.econbiz.de/10010339071
-patent pharmaceuticals. We present a theoretical model with price-sensitive and loyal consumers that shows that a decrease in the reference …
Persistent link: https://www.econbiz.de/10010489291
I study the effect of reference pricing on competition by parallel imports, in particular the market share of parallel imports and the number of parallel traders. First, I analyze the effect of reference pricing on competition by parallel imports in a vertical differentiation model with a...
Persistent link: https://www.econbiz.de/10011949019
This study seeks to provide evidence for deciding whether or not a pharmaceutical innovation should be included in the benefit list of social health insurance. A discrete choice experiment (DCE) was conducted in Germany to measure preferences for modern insulin therapy. Of the 1,100 individuals...
Persistent link: https://www.econbiz.de/10003900791
Many countries with national health care providers and health insurances regulate the market for pharmaceuticals to … (no. of firms) suggests a significant but small negative correlation with prices. -- pharmaceuticals ; prices ; co …
Persistent link: https://www.econbiz.de/10009522774
The major German health care reforms undertaken since the late 1990s resulted in the adoption of selective contracting mechanisms in a formerly sectorally separated health care system. These reforms marked the launch of managed care in Germany that is expected to yield both a higher quality of...
Persistent link: https://www.econbiz.de/10010189584
- manufacturer prices of pharmaceuticals at market entry (though distribution margins are regulated for reimbursed drugs). On the …
Persistent link: https://www.econbiz.de/10014211777